Abstract Number: 2197 • ACR Convergence 2023
Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors
Background/Purpose: Despite efforts for early detection, delayed diagnosis in axial spondyloarthritis (axSpA) remains an unresolved challenge. This analysis aimed to assess diagnostic delay and its…Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…Abstract Number: 1182 • ACR Convergence 2023
Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare, heterogeneous diseases characterized by chronic skeletal muscle inflammation and weakness. Initial conventional therapy is based on expert opinion…Abstract Number: 1295 • ACR Convergence 2023
Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort
Background/Purpose: Early RA patients may present with more tender than swollen joints, which can persist during DMARD therapy. Elevated TSJD (tender-swollen joint difference) is often…Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…Abstract Number: 2025 • ACR Convergence 2023
Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
Background/Purpose: Osteoporosis (OP) treatment options have different attributes based on mode of administration, frequency of administration, risks of minor and serious side effects, and effectiveness,…Abstract Number: 2198 • ACR Convergence 2023
Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Background/Purpose: Active axial spondyloarthritis (axSpA) is associated with poorer physical and mental health outcomes. This study aims to assess the prevalence of clinically active disease…Abstract Number: PP02 • ACR Convergence 2023
Patient Centered Care: The Complete Picture
Background/Purpose: My recollection is that in I997 there about, I began to feel sick and I experienced these symptoms, night sweats, pain in my chest,…Abstract Number: 0025 • ACR Convergence 2023
Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis
Background/Purpose: Cannabinoid receptor 2 (CB2) is a member of the cannabinoid receptor family and is encoded by the CNR2 gene. CB2 receptors are found primarily…Abstract Number: 0397 • ACR Convergence 2023
Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire
Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the…Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…Abstract Number: 1200 • ACR Convergence 2023
Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain
Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…Abstract Number: 1303 • ACR Convergence 2023
Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 43
- Next Page »